Revenues increased but earnings decreased in the fourth quarter for Salt Lake City-based Myriad Genetics, Inc.
The molecular-diagnostic company, which discovers and commercializes tests assessing a person's risk of developing a disease, had a net quarterly income of $37.1 million in the quarter ending June 30, down from $44.1 million a year earlier. That equates to 48 cents per share.
Earnings were based on an 8.4 percent increase in revenues, from $174 million to $189.
"Myriad had an outstanding year as we launched a record three new products and closed a major strategic acquisition," said President and CEO Peter Meldrum, referring to the purchase in February of Crescendo Bioscience.